Beijing Polypeptide Bio Logo

News Center

Stay updated on the latest developments at Beijing Peptide Biotech and cutting-edge news in the peptide drug industry.

2026-08-11·Industry News

For the first time, humans design 16 entirely new viruses using artificial intelligence—a breakthrough with both promise and peril.

The AI-generated virus created in this study poses no threat to humans. It is fundamentally a bacteriophage—a naturally occurring virus that infects only bacteria. According to the latest report by The New York Times, researchers have for the first time used artificial intelligence to design an entirely new virus from scratch. While this breakthrough could enable scientists to develop novel approaches for disease research and infection treatment, it also raises serious biosecurity concerns.

2026-07-30·Company News

Beijing Polypeptide Biotech Unveils Redesigned Global Website to Advance Peptide CDMO Digitalization

BEIJING, July 30, 2026 — Beijing Polypeptide Biotech, a leading China-based technology-driven peptide drug R&D and manufacturing enterprise with over 20 years of industry experience, announces the full launch of its upgraded official website: https://www.peptide-bio.com/. The newly redesigned portal reconstructs the company’s comprehensive peptide service ecosystem, covering custom research peptides, catalog peptide supply, cGMP-grade pharmaceutical intermediates, and non-natural amino acid synthesis.

2026-07-30·Company News

Now Live | Beijing Peptide Biotechnology Unveils New Global Website, Launching a Digital Gateway for Worldwide Peptide Technology Services

Beijing Polypeptide Biotechnology Co., Ltd. launches its new official website (https://www.peptide-bio.com/)正式焕新上线。新版网站围绕公司二十余年多肽研发制造核心优势重构数字化服务体系,整合定制多肽合成、科研多肽、GMP). This one-stop online platform for peptide technical services offers intuitive information, streamlined service, and efficient communication to pharmaceutical companies, biotech firms, universities, and research institutions worldwide, covering all business segments of pharmaceutical intermediates and non-natural amino acid synthesis.

2026-07-30·Industry News

AstraZeneca Q2 Results and Elecoglipron Phase 3 Launch; TGA GLP-1 NAION Warning

AstraZeneca Q2 earnings beat + elecoglipron Phase 3 initiation. AIDS 2026 opens. Australia TGA GLP-1 NAION warning. Hims $44M peptide analyst outlook.

2026-07-30·Industry News

GLP-1s No Benefit in Stable IBD; Kiniksa Q2 (ARCALYST +55% YoY); Medicare Bridge 27 Days In

Tuesday's digest is anchored by two clinical-and-payer stories on GLP-1 receptor agonists that complicate the class's uniformly positive narrative. First, a Medscape-published emulated randomized trial analysis using 2018-2023 US claims data found that adults with stable inflammatory bowel disease and comorbid obesity or diabetes who initiated semaglutide or tirzepatide did not have a lower risk of IBD relapse or improved safety outcomes versus non-initiators. The finding challenges the anti-inf

2026-07-30·Industry News

AIDS 2026 ISLEND Late-Breaker, PURPOSE 1/2 52-Week OLE, Biogen Q2 Beat + LEQEMBI IQLIK At-Home Dosing

AIDS 2026 late-breaker: Gilead-Merck ISL/LEN Week 48 details. PURPOSE 1/2 52-week OLE. Biogen Q2 beats estimates + LEQEMBI IQLIK approved. Alnylam Q2 preview Thursday. 4 stories · Covering clinical trials and industry

Jing ICP Bei 2025147821 Hao-1